谭永红 张培炽 郑成位 400042 重庆，第三军医大学附属大坪医院肿瘤科 中华肿瘤杂志 1999 0 21 4


    关键词：肺肿瘤；癌，非小细胞肺；肿瘤标记物 期刊 zhzlzz 0 临床研究 fur -->


    

【摘要】 目的 研究CYFRA21-1作为血清肿瘤标记物对非小细胞肺癌诊断及病情、疗效判断的临床应用价值。方法 分别于术前、术后2周、术后15～18个月采集非小细胞肺癌患者血清样本共126份，用放射免疫分析法检测其CYFRA21-1含量。结果 初治的非小细胞肺癌患者CYFRA21-1总阳性率为49.3%，其中鳞癌69.2%，腺癌25.0%。鳞癌患者的血清CYFRA21-1含量显著高于腺癌(P<0.0001)。血清CYFRA21-1含量与临床TNM分期显著相关(P=0.0001)，随期别增加而升高。CYFRA21-1含量在术后2周显著下降(P=0.0005)。术后2周与术后15～18个月的血清样本中CYFRA21-1含量比较：病情稳定者，CYFRA21-1含量无明显升高(P=0.6233)；病情进展者，CYFRA21-1含量明显升高(P=0.0051)。结论 CYFRA21-1检测对非小细胞肺癌患者的诊断、病情监视和疗效判断有较高的临床应用价值。

Usefulness of CYFRA21-1 as a tumormarker of non-small-cell lung cancer

TAN Yonghong, ZHANG Peichi, ZHENG Chengwei.Department of Oncology, Daping Hospital, Third Military Medical University, Chongqing400042

【Abstract】 Objective Toevaluate the clinical usefulness of CYFRA21-1 as a serum tumor marker in diagnosis,evaluation of clinical status and prognosis of patients with non-small-cell lung cancer (NSCLC). Methods CYFRA21-1 in 126 serum samples of NSCLC patients wasmeasured by radioimmunoassay. Of the 126 samples, 71 were collected before treatment, 29at two weeks after operation, and 26 after 15～18 months follow-up.Results CYFRA21-1was positive in 49.3% of the NSCLC patients who had not received any treatment. Thepositive rate was 69.2% for squamous-cell carcinoma, and 25.0% for adenocarcinoma. Theserum level of CYFRA21-1 was significantly higher in squamous-cell carcinoma than inadenocarcinoma (P<0.0001). The serum level of CYFRA21-1 well correlated and increasedwith TNM staging (P=0.0001). The level decreased significantly within two weeks aftersurgical operation in 29 cases (P=0.0005). On follow up for 15～18 months, no change inCYFRA21-1 level was obseved in 16 patients whose disease was stable, while there wassignificant increase in 10 patients with progressive disease. Conclusion CYFRA21-1is a soluble fragment of cytokeratin 19 in serum of patients with NSCLC. It can be used asa useful tumor marker of NSCLC.

     ......